

Study on the tolerance and efficiency of a dermo-cosmetic product for mild to moderate acne in combination or comparison to current treatments in Romania

Submission date 01/02/2023	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
Registration date 11/12/2023	Overall study status Completed	<input type="checkbox"/> Protocol
Last Edited 04/11/2024	Condition category Skin and Connective Tissue Diseases	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Background and study aims

The aim of this study is to evaluate Teen Derm A.Z, a triple action care against persistent blemishes and marks and ultra-soothing that is applied on the face area.

Who can participate?

Patients with acne-prone skin. For groups 2 and 3 patients should begin an anti-acne treatment (zinc orally, antibiotic orally, contraceptive or hormonal treatment, topical retinoid, or a combination of these treatments).

What does the study involve?

First, the tolerance (cutaneous acceptability) of the treatment will be evaluated by clinical examination under dermatological control. Then, the effectiveness of the product in reducing acne lesions and marks (red and brown) will be assessed by the use of dermatological scoring and by comparing before and after pictures. Patient quality of life will be assessed and cosmetic acceptability and future use will be evaluated using a questionnaire.

What are the possible benefits and risks of participating?

The possible benefits are the improvement of acne severity.

Where is the study run from?

The study is run from two private dermatologists' offices in Romania

When is the study starting and how long is it expected to run for?

September 2022 to September 2023

Who is funding the study?

ISISPHARMA (France)

Who is the main contact?
Amélie Clément, aclement@isispharma.com

Contact information

Type(s)

Principal investigator

Contact name

Dr Kaleshtari Mohammad Hatami

Contact details

CUI 21047847
Bulevardul Ferdinand I 12A
Bucarest
Romania
021391
+40 (0)212520520
hatamiafs@yahoo.com

Type(s)

Principal investigator

Contact name

Dr Aura Vladuti

Contact details

CUI 24519243, Strada Octav
Cocarascu nr 57
Bucarest
Romania
-
+40 (0)723235601
doctor.derma@yahoo.com

Type(s)

Scientific

Contact name

Dr Carine Mainzer

Contact details

78 rue de la Villette
Lyon
France
69003
+33 (0)4 28 00 04 00
cmainzer@isispharma.com

Type(s)

Public

Contact name

Ms Amélie Clément

Contact details

78 rue de la Villette

Lyon

France

69003

+33 (0)6 29 76 53 54

aclement@isispharma.com

Additional identifiers

Clinical Trials Information System (CTIS)

Nil known

ClinicalTrials.gov (NCT)

Nil known

Protocol serial number

2022-01

Study information

Scientific Title

Comparative efficacy and tolerability of a novel dermo-cosmetic cream with 15% azelaic acid for mild to moderate acne: a promising alternative to antibiotics

Study objectives

The product offers a good tolerance thanks to additional active ingredients and good efficacy on inflammatory lesions thanks to 15% azelaic acid.

Ethics approval required

Ethics approval not required

Ethics approval(s)

The study does not require ethics committee approval because it is conducted in private offices in Romania

Study design

Open-label observational study

Primary study design

Observational

Study type(s)

Quality of life, Treatment, Safety, Efficacy

Health condition(s) or problem(s) studied

Mild to moderate acne-prone skin

Interventions

The evaluated product is a cosmetic.

Group 1: only the cosmetic product applied twice per day

Group 2: cosmetic product applied once per day + concomitant treatment (according to the prescribing habits/needs of each patient)

Group 3: usual treatment according to the prescribing habits/needs of each patient

Evaluation of the tolerance (cutaneous acceptability) by clinical examination under dermatological control after 42 and 84 days of treatment

Evaluation of the efficacy in reducing acne lesions and marks (red and brown) by use of dermatological scoring at baseline and after 42 and 84 days

Evaluation of the global amelioration with before/after pictures at days 0, 42, and 84

Evaluation of the improvement of patient quality of life with the Cardiff Acne Disability Index (CADI) at days 0 and 84

Evaluation of the cosmetic acceptability and future use of the product by analysis of the subject's answers to a subjective evaluation questionnaire on day 84

After 112 days, evaluation of the effects of stopping the treatment or product use after 1 month

Intervention Type

Other

Primary outcome(s)

Tolerance (cutaneous acceptability) by clinical examination under dermatological control at baseline, 42, 84, and 72 days

Key secondary outcome(s)

1. Efficacy in reducing acne lesions and marks (red and brown) measured using dermatological scoring on days 0, 42, 84, and 112
2. Quality of life measured using the Cardiff Acne Disability Index (CADI) at days 0, 84 and 112

Completion date

30/09/2023

Eligibility

Key inclusion criteria

1. Sex: female and/or male
2. Subject having given his/her informed written consent or parental authorization
3. Subject willing to adhere to the protocol and study procedures

Specific criteria:

1. Healthy subject with acne-prone skin: grade 2 or 3 (Global Acne Evaluation [GEA] scale) and with at least 10 inflammatory lesions
2. Group 2 and 3: Beginning an anti-acne treatment (zinc orally, antibiotic orally, contraceptive or hormonal treatment, topical retinoid or a combination)

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Mixed

Sex

All

Total final enrolment

90

Key exclusion criteria

1. Excluding treatment:

1.1. Epiduo® or combination of benzoyl peroxide (BPO) + Adapalene

1.2. Oral isotretinoin

1.3. Chronically used anti-inflammatory drugs

2. Subject manipulating his/her acneic lesions

3. Any change in hormonal treatment (including contraceptives) during the three previous months of the study

4. Cutaneous pathology on the study zone (eczema, etc)

5. Excessive exposure to sunlight or UV rays within the previous month

6. Subject enrolled in another clinical trial during the study period

Date of first enrolment

01/10/2022

Date of final enrolment

01/03/2023

Locations

Countries of recruitment

Romania

Study participating centre

CMI Dermato-Venerologie, Afshin Hatami

Bulevardul Ferdinand I 12A

Bucarest

Romania

021391

Study participating centre

CMI Dr Aura Vladuti Dermatovenerologie

Strada Octav Cocarascu nr 57

Bucarest
Romania

-

Sponsor information

Organisation
ISISPHARMA

Funder(s)

Funder type
Industry

Funder Name
ISISPHARMA

Results and Publications

Individual participant data (IPD) sharing plan

Individual participant data are irretrievably and definitively anonymized, without the possibility of identification of the participant concerned, by the Investigator according to the standards in force guaranteeing complete confidentiality, prior to any transmission, display, or transfer to anyone.

IPD sharing plan summary

Not expected to be made available

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article		02/11/2024	04/11/2024	Yes	No
Basic results			04/07/2024	No	No